Glivec Research Today is a free monthly online journal that collates and summarizes the latest research about Glivec, including details on gleevec, imatinib, cancer, treatment, side-effects.

Volume 3 (2006), Issue 11 (November)

1. Mathematical models of targeted cancer therapy.
   Br J Cancer, 95(9): 1136-41. [Abstract] [Full-text]
2. Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate.
   BMC Gastroenterol, 6: 29. [Abstract] [Full-text]
3. Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease.
   Am J Respir Crit Care Med, 174(10): 1145-52. [Abstract] [Full-text]
4. CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53.
   Blood, 108(10): 3450-7. [Abstract] [Full-text]
5. The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells.
   Blood, 108(10): 3538-47. [Abstract] [Full-text]
6. Newly identified c-KIT receptor tyrosine kinase ITD in childhood AML induces ligand-independent growth and is responsive to a synergistic effect of imatinib and rapamycin.
   Blood, 108(10): 3504-13. [Abstract] [Full-text]
7. NUP214-ABL1 in adult T-ALL: the GMALL study group experience.
   Blood, 108(10): 3556-9. [Abstract] [Full-text]
8. Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.
   Blood, 108(10): 3406-13. [Abstract] [Full-text]
9. Ability of breast cancer cell lines to stimulate bone resorbing activity of mature osteoclasts correlates with an anti-apoptotic effect mediated by macrophage colony stimulating factor.
   Apoptosis, 11(11): 1909-1921. [Abstract] [Full-text]
10. Imatinib mesylate (Gleevec(R)) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.
    Eur J Pharmacol, 551(1): 27-33. [Abstract] [Full-text]
11. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    Clin Cancer Res, 12(21): 6540-6. [Abstract] [Full-text]
12. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
    Clin Cancer Res, 12(21): 6494-501. [Abstract] [Full-text]
13. Selective binding of imatinib to the genetic variants of human alpha1-acid glycoprotein.
    Biochim Biophys Acta, 1760(11): 1704-12. [Abstract] [Full-text]
14. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
    Mol Cancer, 5: 46. [Abstract] [Full-text]
15. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
    Proc Natl Acad Sci U S A, 103(45): 16870-5. [Abstract] [Full-text]
16. Could ATRA/Idarubicin treatment of acute promyelocytic leukemia induce the appearance of new clonal cytogenetic abnormalities in patients in complete remission?
    Leuk Res. [Abstract] [Full-text]
17. Nuclear positioning of the BACH2 gene in BCR-ABL positive leukemic cells.
    Genes Chromosomes Cancer, 46(1): 67-74. [Abstract] [Full-text]
18. New approaches to molecular cancer therapeutics.
    Nat Chem Biol, 2(12): 689-700. [Abstract] [Full-text]
19. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Cancer Res, 66(22): 10959-66. [Abstract] [Full-text]
20. Novel treatment strategies for chronic myeloid leukemia.
    Am J Health Syst Pharm, 63(23): S15-20. [Abstract] [Full-text]
21. Chronic myeloid leukemia: Standard treatment options.
    Am J Health Syst Pharm, 63(23): S10-4. [Abstract] [Full-text]
22. Imatinib mesylate (Gleevec) protects against streptozotocin-induced diabetes and islet cell death in vitro.
    Cell Biol Int, 30(12): 1013-7. [Abstract] [Full-text]
23. Gastrointestinal stromal tumors: A contemporary review.
    Pathol Res Pract, 202(12): 837-47. [Abstract] [Full-text]
24. Oral Administration of Imatinib to P230 BCR/ABL-Expressing Transgenic Mice Changes Clones with High BCR/ABL Complementary DNA Expression into Those with Low Expression.
    Int J Hematol, 84(4): 346-53. [Abstract] [Full-text]
25. Mesenteric gastrointestinal stromal tumour presenting as intracranial space occupying lesion.
    World J Surg Oncol, 4: 78. [Abstract] [Full-text]
26. Improving upon the promise of targeted therapy of human malignancy: chronic myeloid leukemia as a paradigm.
    Cancer Chemother Pharmacol, 58: 49-53. [Abstract] [Full-text]
27. Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor.
    Cancer Chemother Pharmacol, 58: 55-61. [Abstract] [Full-text]
28. Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells.
    J Cell Biochem, 99(6): 1553-63. [Abstract] [Full-text]
29. Influence of hydroxyurea on imatinib mesylate (gleevec) transport at the mouse blood-brain barrier.
    Drug Metab Dispos, 34(12): 1945-9. [Abstract] [Full-text]

© 2004-2008 Glivec Research Today. All Rights Reserved.